Bartalena L, Brogioni S, Grasso L, Rago T, Vitti P, Pinchera A, Martino E
Istituto di Endocrinologia, University of Pisa, Italy.
J Clin Endocrinol Metab. 1994 Nov;79(5):1424-7. doi: 10.1210/jcem.79.5.7962338.
Increased serum interleukin-6 (IL-6) concentrations have recently been reported in patients with subacute thyroiditis and in some patients with amiodarone-induced thyrotoxicosis, possibly because of cytokine release from damaged thyroid cells. In this study, serum IL-6 levels were determined by an enzyme-linked immunosorbent assay method in 18 patients given percutaneous intranodular ethanol injection (PIEI) for autonomously functioning thyroid nodule, 12 patients treated with radioactive iodine (RAI) for Graves' disease or toxic adenoma, and 23 patients submitted to fine needle aspiration (FNA) for nonfunctioning thyroid nodules. Baseline serum IL-6 levels did not differ in the 3 groups. PIEI was followed by a dramatic increase in median IL-6 values from 42 fmol/L (range, < 25 to 84) to 381 fmol/L (range, 61-9870; P < 0.0001); the peak value was attained as little as 10 min after injection. RAI was also followed by a significant (P < 0.0001) increase in IL-6 from 52 fmol/L (range, < 25 to 84) to 189 fmol/L (range, 119-1417 fmol/L); the increase after RAI was lower than that after PIEI (P < 0.05), and the peak value was attained later (after 24 h). FNA was also followed by a slight, but significant, increase in the serum IL-6 concentration from 21 fmol/L (range, < 25 to 103) to 109 fmol/L (range, < 25 to 360; P < 0.0001 vs. baseline). The increase in IL-6 was correlated with the size of nodule or goiter (P < 0.0001), but not with the amount of injected ethanol or the dose of radioiodine delivered to the thyroid. Serum thyroglobulin also increased after PIEI, RAI, or FNA, but no significant correlation could be demonstrated with the increase in IL-6. The results of this study support the concept that in the absence of nonthyroidal illnesses, which are often associated with increased serum concentrations of the cytokine, IL-6 can be regarded as a useful marker of thyroid-destructive processes.
最近有报道称,亚急性甲状腺炎患者以及一些胺碘酮所致甲状腺毒症患者的血清白细胞介素-6(IL-6)浓度升高,这可能是由于受损甲状腺细胞释放细胞因子所致。在本研究中,采用酶联免疫吸附测定法测定了18例因自主性甲状腺结节接受经皮结节内乙醇注射(PIEI)治疗的患者、12例因格雷夫斯病或毒性腺瘤接受放射性碘(RAI)治疗的患者以及23例因无功能甲状腺结节接受细针穿刺抽吸(FNA)的患者的血清IL-6水平。三组患者的基线血清IL-6水平无差异。PIEI后,IL-6中位数显著升高,从42 fmol/L(范围,<25至84)升至381 fmol/L(范围,61 - 9870;P<0.0001);注射后仅10分钟即达到峰值。RAI后IL-6也显著升高(P<0.0001),从52 fmol/L(范围,<25至84)升至189 fmol/L(范围,119 - 1417 fmol/L);RAI后的升高低于PIEI后的升高(P<0.05),且峰值出现较晚(24小时后)。FNA后血清IL-6浓度也有轻微但显著的升高,从21 fmol/L(范围,<25至103)升至109 fmol/L(范围,<25至360;与基线相比P<0.0001)。IL-6的升高与结节或甲状腺肿的大小相关(P<0.0001),但与注射乙醇的量或给予甲状腺的放射性碘剂量无关。PIEI、RAI或FNA后血清甲状腺球蛋白也升高,但与IL-6的升高无显著相关性。本研究结果支持以下观点:在不存在通常与细胞因子血清浓度升高相关的非甲状腺疾病的情况下,IL-6可被视为甲状腺破坏过程的有用标志物。